Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of “Buy” by Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRSGet Rating) has been given a consensus recommendation of “Buy” by the seven brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $36.00.

A number of research analysts recently commented on the company. StockNews.com assumed coverage on Aclaris Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Aclaris Therapeutics in a research note on Friday, February 25th. Zacks Investment Research cut Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Aclaris Therapeutics in a research note on Monday, December 20th.

Shares of ACRS opened at $17.01 on Friday. The company has a market cap of $1.04 billion, a P/E ratio of -10.44 and a beta of 0.46. The stock has a fifty day moving average price of $15.43 and a 200 day moving average price of $14.57. Aclaris Therapeutics has a 12 month low of $9.26 and a 12 month high of $28.25.

Aclaris Therapeutics (NASDAQ:ACRSGet Rating) last issued its quarterly earnings data on Thursday, February 24th. The biotechnology company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.01). The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.80 million. Aclaris Therapeutics had a negative return on equity of 47.82% and a negative net margin of 1,343.96%. The business’s quarterly revenue was down 5.1% on a year-over-year basis. Equities analysts predict that Aclaris Therapeutics will post -1.84 EPS for the current year.

In related news, CFO Frank Ruffo sold 12,823 shares of the firm’s stock in a transaction dated Thursday, March 10th. The stock was sold at an average price of $15.55, for a total transaction of $199,397.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Neal Walker sold 56,303 shares of the firm’s stock in a transaction dated Friday, March 11th. The shares were sold at an average price of $15.91, for a total value of $895,780.73. The disclosure for this sale can be found here. Insiders have sold 96,674 shares of company stock valued at $1,526,797 in the last ninety days. Company insiders own 8.20% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in ACRS. TCG Crossover Management LLC purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter valued at $15,735,000. Wellington Management Group LLP lifted its holdings in shares of Aclaris Therapeutics by 15.4% during the third quarter. Wellington Management Group LLP now owns 5,420,453 shares of the biotechnology company’s stock valued at $97,568,000 after purchasing an additional 722,704 shares during the last quarter. Laurion Capital Management LP lifted its holdings in shares of Aclaris Therapeutics by 126.4% during the fourth quarter. Laurion Capital Management LP now owns 1,115,075 shares of the biotechnology company’s stock valued at $16,213,000 after purchasing an additional 622,575 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Aclaris Therapeutics by 17.0% during the third quarter. BlackRock Inc. now owns 3,788,417 shares of the biotechnology company’s stock valued at $68,192,000 after purchasing an additional 549,368 shares during the last quarter. Finally, Commodore Capital LP lifted its holdings in shares of Aclaris Therapeutics by 31.2% during the third quarter. Commodore Capital LP now owns 2,190,291 shares of the biotechnology company’s stock valued at $39,425,000 after purchasing an additional 521,304 shares during the last quarter. 98.62% of the stock is owned by institutional investors and hedge funds.

About Aclaris Therapeutics (Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

See Also

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.